Erlotinib Hydrochloride: A Targeted Therapy for Advanced Cancers
Revolutionizing cancer treatment with precise EGFR inhibition for lung and pancreatic cancers.
Get a Quote & SampleProduct Core Value
Erlotinib Hydrochloride
Erlotinib Hydrochloride is a potent targeted therapy designed to combat specific types of cancer by precisely inhibiting the epidermal growth factor receptor (EGFR). Its primary applications are in the treatment of metastatic non-small cell lung cancer (NSCLC) that exhibits certain EGFR gene mutations, and advanced pancreatic cancer, often administered in conjunction with gemcitabine. This advanced pharmaceutical active ingredient offers a mechanism of action that interferes with cancer cell proliferation, representing a significant advancement in oncology.
- Understanding the erlotinib hydrochloride mechanism of action reveals its critical role in blocking cancer cell growth signals, making it a key component in targeted cancer therapy.
- The erlotinib hydrochloride for lung cancer treatment is specifically indicated for patients with specific EGFR mutations, highlighting the personalized nature of this therapy.
- Erlotinib hydrochloride for pancreatic cancer is typically used alongside other chemotherapy drugs, demonstrating its versatility in complex treatment regimens.
- Thorough knowledge of erlotinib hydrochloride side effects and erlotinib hydrochloride drug interactions is paramount for safe and effective patient care.
Key Advantages
Precision Targeting
Erlotinib hydrochloride offers precise targeting of cancer cells with specific EGFR mutations, minimizing damage to healthy cells and enhancing treatment efficacy through its targeted cancer therapy approach.
Oral Administration Convenience
As an orally administered medication, erlotinib hydrochloride provides convenience for patients, simplifying treatment delivery compared to intravenous therapies and improving patient compliance.
Established Efficacy
The established efficacy of erlotinib hydrochloride in treating advanced non-small cell lung cancer and pancreatic cancer underscores its importance as a frontline or combination therapy in modern oncology.
Key Applications
Non-Small Cell Lung Cancer (NSCLC)
Used for metastatic NSCLC in patients with specific EGFR mutations, demonstrating effectiveness in targeted cancer therapy.
Pancreatic Cancer
Administered in combination with gemcitabine for advanced pancreatic cancer, showcasing its role in multi-modal treatment strategies.
Personalized Medicine
Represents a cornerstone of personalized medicine by targeting specific genetic profiles within tumors for optimized outcomes.
Oncology Research
Serves as a critical research compound for studies in oncology, drug development, and understanding resistance mechanisms.